111 related articles for article (PubMed ID: 6279339)
1. Pseudodeficiency of alpha-galactosidase A.
Bach G; Rosenmann E; Karni A; Cohen T
Clin Genet; 1982 Jan; 21(1):59-64. PubMed ID: 6279339
[TBL] [Abstract][Full Text] [Related]
2. [Biochemical diagnosis of Anderson-Fabry disease in two brothers].
Vidershaĭn GIa; Beĭer EM; Mendel'son MM; Livandovskiĭ IuA
Vopr Med Khim; 1986; 32(5):120-3. PubMed ID: 3095985
[TBL] [Abstract][Full Text] [Related]
3. Pseudo-clinical Fabry's disease without alpha galactosidase deficiency.
Peltier A; Herbeuval E; Brondeau MT; Belleville F; Nabet P
Biomedicine; 1977 May; 26(3):194-201. PubMed ID: 407951
[TBL] [Abstract][Full Text] [Related]
4. Heterozygote detection in Fabry disease utilizing multiple enzyme activities.
Sheth KJ; Good TA; Murphy JV
Am J Med Genet; 1981; 10(2):141-6. PubMed ID: 6274191
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease. Mutations in brief no. 169. Online.
Chen CH; Shyu PW; Wu SJ; Sheu SS; Desnick RJ; Hsiao KJ
Hum Mutat; 1998; 11(4):328-30. PubMed ID: 9554750
[TBL] [Abstract][Full Text] [Related]
6. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.
Miyamura N; Araki E; Matsuda K; Yoshimura R; Furukawa N; Tsuruzoe K; Shirotani T; Kishikawa H; Yamaguchi K; Shichiri M
J Clin Invest; 1996 Oct; 98(8):1809-17. PubMed ID: 8878432
[TBL] [Abstract][Full Text] [Related]
7. [Molecular genetics of inherited metabolic diseases--its application to the investigation of pathogenesis and the diagnosis of Fabry disease].
Sakuraba H
Rinsho Byori; 1994 Jun; 42(6):628-35. PubMed ID: 7914243
[TBL] [Abstract][Full Text] [Related]
8. [Angiokeratoma corporis diffusum (Fabry's disease). Update. Apropos of 2 cases].
Larralde de Luna M; García Díaz R; Sánchez G; Ilari R; Pierini AM; Campoy C; Chamoles NH
Med Cutan Ibero Lat Am; 1985; 13(2):129-40. PubMed ID: 2995736
[TBL] [Abstract][Full Text] [Related]
9. A successful approach for the detection of Fabry patients in Argentina.
Rozenfeld PA; Tarabuso A; Ebner R; Ramallo G; Fossati CA
Clin Genet; 2006 Apr; 69(4):344-8. PubMed ID: 16630168
[TBL] [Abstract][Full Text] [Related]
10. Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy.
Sawada K; Mizoguchi K; Hishida A; Kaneko E; Koide Y; Nishimura K; Kimura M
Clin Nephrol; 1996 May; 45(5):289-94. PubMed ID: 8738659
[TBL] [Abstract][Full Text] [Related]
11. [alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].
Okumiya T; Takata T; Sasaki M; Sakuraba H
Rinsho Byori; 1997 Feb; 45(2):127-35. PubMed ID: 9120996
[TBL] [Abstract][Full Text] [Related]
12. [Biochemical study of unusual cases of Fabry disease].
Beĭer EM; Karpova EA; Udalova OV; Tsvetkova IV
Vopr Med Khim; 1998; 44(5):494-500. PubMed ID: 9916266
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Fabry disease.
Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
[TBL] [Abstract][Full Text] [Related]
14. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients.
Navarro C; Teijeira S; Dominguez C; Fernandez JM; Rivas E; Fachal C; Barrera S; Rodriguez C; Iranzo P
Acta Neuropathol; 2006 Feb; 111(2):178-85. PubMed ID: 16463201
[TBL] [Abstract][Full Text] [Related]
16. A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease.
Rosenthal D; Lien YH; Lager D; Lai LW; Shang S; Leung N; Fervenza FC
Am J Kidney Dis; 2004 Nov; 44(5):e85-9. PubMed ID: 15492942
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
[TBL] [Abstract][Full Text] [Related]
18. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N
J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955
[TBL] [Abstract][Full Text] [Related]
20. A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease.
Konoshita T; Mutoh H; Yokoi T; Koni I; Miyamori I; Mabuchi H
Clin Nephrol; 2001 Mar; 55(3):243-7. PubMed ID: 11316246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
